Why the study?
Monitoring anti-factor Xa levels remains controversial due to resource utilization and unclear guidelines, and optimal enoxaparin dosing in high-risk populations has not been determined.
Does enoxaparin monitoring via anti-factor Xa levels improve safety and efficacy in high-risk patient populations?
Population
Fourteen studies of high-risk patients with low body weight, obesity, renal insufficiency, or pregnancy
Comparison
Enoxaparin monitoring via anti-factor Xa levels vs unmonitored or standard dosing
Design
Systematic review of randomized controlled trials and meta-analyses
Authors
Loading...
Anti-Xa monitoring for enoxaparin in high-risk patients needs clearer guidance; extends conditional recommendations for individualized dosing in obesity, renal insufficiency, and pregnancy.
Does enoxaparin monitoring via anti-factor Xa levels improve safety and efficacy in high-risk patient populations?
Anti-factor Xa level monitoring may be necessary for enoxaparin dosing in high-risk patients (extremes of weight, renal insufficiency, pregnancy) to prevent adverse events.
Sikes et al. (2023) studied this question.